WIL2-NS (ATCC® CRL-8155)

Organism: Homo sapiens, human  /  Cell Type: B lymphocyte  / 

Permits and Restrictions

View Permits

Organism Homo sapiens, human
Cell Type B lymphocyte
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 2
Age 5 years
Gender male
Ethnicity Caucasian
Applications
transfection host
Derivation
The line was derived from the WIL-2 B cell line.
Clinical Data
male
Caucasian
5 years
Comments
This line does not secrete immunoglobulin.
The line was derived from the WIL-2 B cell line.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Medium Renewal: Every 2 to 3 days
Cultures can be maintained by addition or replacement of fresh medium. Start cultures at 2 X 10 exp5 cells/ml and maintain between 1 X 10 exp5 and 1 X 10 exp6 cells/ml.
Cryopreservation
culture medium 95%; DMSO, 5%
Culture Conditions
Temperature: 37.0°C
STR Profile
Amelogenin: X,Y
CSF1PO: 11,12
D13S317: 11
D16S539: 11,12
D5S818: 12,13
D7S820: 9,12
F13A01: 6,7
F13B: 10
FESFPS: 11,12
LPL: 9,10
THO1: 8,9.3
TPOX: 8,11
vWA: 17,20
Name of Depositor TA Coons
References

Levy JA, et al. Human lymphoblastoid lines from lymph node and spleen. Cancer 22: 517-524, 1968. PubMed: 5673231

Alspaugh MA, Tan EM. Antibodies to cellular antigens in Sjogren's syndrome. J. Clin. Invest. 55: 1067-1073, 1975. PubMed: 804494

Vaughan JH, et al. Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen. US Patent 4,654,419 dated Mar 31 1987

Vaughan JH, et al. Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides. US Patent 5,116,725 dated May 26 1992

Vaughan JH, et al. Assay of anti-Epstein-Barr virus nuclear antigen antibodies with synthetic polypeptides. US Patent 5,122,448 dated Jun 16 1992

Levy JA, et al. Further characterization of the WI-L1 and WI-L2 lymphoblastoid lines. J. Natl. Cancer Inst. 46: 647-654, 1971. PubMed: 4323138

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Levy JA, et al. Human lymphoblastoid lines from lymph node and spleen. Cancer 22: 517-524, 1968. PubMed: 5673231

Alspaugh MA, Tan EM. Antibodies to cellular antigens in Sjogren's syndrome. J. Clin. Invest. 55: 1067-1073, 1975. PubMed: 804494

Vaughan JH, et al. Synthetic polypeptides and antibodies related to epstein-barr virus nuclear antigen. US Patent 4,654,419 dated Mar 31 1987

Vaughan JH, et al. Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides. US Patent 5,116,725 dated May 26 1992

Vaughan JH, et al. Assay of anti-Epstein-Barr virus nuclear antigen antibodies with synthetic polypeptides. US Patent 5,122,448 dated Jun 16 1992

Levy JA, et al. Further characterization of the WI-L1 and WI-L2 lymphoblastoid lines. J. Natl. Cancer Inst. 46: 647-654, 1971. PubMed: 4323138